Afdhal NH, Giannini EG, Tayyab G, et al; ELEVATE Study Group. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. N Engl J Med. 2012;367:716-724.
Al-Samkari H, Aggarwal K, Vredenburg M, et al. Long-term response rates in patients with chronic immune thrombocytopenia treated with avatrombopag: additional analyses from a phase 3 study and its extension phase. Blood. 2019;134(suppl_1):2356.
Al-Samkari H, Nagalla S. Efficacy and safety evaluation of avatrombopag in immune thrombocytopenia: analyses of a phase III study and long-term extension. Platelets. 2021. doi: 10.1080/09537104.2021.1881952. [Epub ahead of print]
Blinder M, Vredenburg M, Tian W, et al. Consistent efficacy demonstrated by avatrombopag in immune thrombocytopenia (ITP) regardless of the number of lines of prior ITP treatment. Presented at: 62nd ASH Annual Meeting and Exposition; December 5-8, 2020; Virtual. Abstract 835.
Cheng G, Saleh MN, Marcher C, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet. 2011;377:393-402.
Cines DB, Wasser J, Rodeghiero F, et al. Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia. Haematologica. 2017;102:1342-1351.
Doptelet® (avatrombopag) [prescribing information]. AkaRx, Inc. Approved 2018. Revised October 2020.
Jurczak W, Chojnowski K, Mayer J, et al. Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia. Brit J Haematol. 2018;183:479-490.
Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet. 2008;371:395-403.
Nagalla S, Vredenburg M, Tian W, et al. Platelet response to avatrombopag in patients with chronic immune thrombocytopenia: additional analyses from a phase 3 study and its extension. Blood. 2019;134(suppl_1):1071.
Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3:3829-3866.
Nplate® (romiplostim) [prescribing information]. Amgen Inc. Approved 2008. Revised February 2021.
Poordad F, Terrault NA, Alkhouri N, et al. Avatrombopag, an alternate treatment option to reduce platelet transfusions in patients with thrombocytopenia and chronic liver disease-integrated analyses of 2 phase 3 studies. Int J Hepatol. 2020;2020:5421632.
Promacta® (eltrombopag) [prescribing information]. Novartis Pharmaceuticals Corporation. Approved 2008. Revised February 2021.
Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019;3:3780-3817.

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.

Moderator

Drew Provan, MD, FRCP, FRCPath

Academic Haematology Unit
Blizard Institute
Barts and The London School of Medicine and Dentistry
Queen Mary University of London
London, United Kingdom

Disclosures

Disclosure: Drew Provan, MD, FRCP, FRCPath, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amgen; Argenx; Novartis; SOBI; UCB
Served as a speaker or a member of a speakers bureau for: Amgen; Novartis
Received grants for clinical research from: Amgen; Novartis
Owns stock, stock options, or bonds from: GlaxoSmithKline

Panelists

Hanny Al-Samkari, MD

Massachusetts General Hospital
Harvard Medical School
Boston, Massachusetts, United States

Disclosures

Disclosure: Hanny Al-Samkari, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Agios; Argenx; Dova; Rigel; SOBI
Received grants for clinical research from: Agios; Amgen; Dova

Maria L. Lozano, MD, PhD

Hospital Universitario Morales Meseguer
Centro Regional de Hemodonación
Universidad de Murcia, IMIB-Arrixaca
Murcia, Spain

Disclosures

Disclosure: Maria L. Lozano, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amgen; Grifols; Novartis; SOBI; UCB
Served as a speaker or a member of a speakers bureau for: Amgen; Macopharma; Novartis; Terumo
Received grants for clinical research from: Amgen; Terumo

Editors

Sanneke Koekkoek

Medical Education Director, WebMD Global, LLC

Disclosures

Disclosure: Sanneke Koekkoek has disclosed no relevant financial relationships.

Yoji Yamaguchi

Associate Scientific Content Manager, WebMD Global, LLC

Disclosures

Disclosure: Yoji Yamaguchi has disclosed no relevant financial relationships.

Content Reviewer

Esther Nyarko, PharmD

Associate Director, Accreditation and Compliance, Medscape LLC

Disclosures

Disclosure: Esther Nyarko, PharmD, has disclosed no relevant financial relationships.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

CPD

TPO-RA in Adult Patients With ITP: Experts Discuss the Latest Developments

Authors: Drew Provan, MD, FRCP, FRCPath; Hanny Al-Samkari, MD; Maria L. Lozano, MD, PhD
CPD Released: 5/7/2021
THIS ACTIVITY HAS EXPIRED
Valid for credit through: 5/7/2022

Start Activity

Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US hematologists.

The goal of this activity is to improve adoption of thrombopoietin receptor agonists (TPO-RAs) in the management of patients with ITP through discussion of key clinical evidence supporting the use of newly approved TPO-RAs in clinical practice.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Current unmet needs in the management of patients with ITP
- Key clinical evidence supporting the use of newly approved TPO-RAs
- Patients who benefit most from use of novel TPO-RAs

Disclosures

Moderator

Drew Provan, MD, FRCP, FRCPath

Academic Haematology Unit
Blizard Institute
Barts and The London School of Medicine and Dentistry
Queen Mary University of London
London, United Kingdom

Disclosures

Disclosure: Drew Provan, MD, FRCP, FRCPath, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amgen; Argenx; Novartis; SOBI; UCB
Served as a speaker or a member of a speakers bureau for: Amgen; Novartis
Received grants for clinical research from: Amgen; Novartis
Owns stock, stock options, or bonds from: GlaxoSmithKline

Panelists

Hanny Al-Samkari, MD

Massachusetts General Hospital
Harvard Medical School
Boston, Massachusetts, United States

Disclosures

Disclosure: Hanny Al-Samkari, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Agios; Argenx; Dova; Rigel; SOBI
Received grants for clinical research from: Agios; Amgen; Dova

Maria L. Lozano, MD, PhD

Hospital Universitario Morales Meseguer
Centro Regional de Hemodonación
Universidad de Murcia, IMIB-Arrixaca
Murcia, Spain

Disclosures

Disclosure: Maria L. Lozano, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amgen; Grifols; Novartis; SOBI; UCB
Served as a speaker or a member of a speakers bureau for: Amgen; Macopharma; Novartis; Terumo
Received grants for clinical research from: Amgen; Terumo

Editors

Sanneke Koekkoek

Medical Education Director, WebMD Global, LLC

Disclosures

Disclosure: Sanneke Koekkoek has disclosed no relevant financial relationships.

Yoji Yamaguchi

Associate Scientific Content Manager, WebMD Global, LLC

Disclosures

Disclosure: Yoji Yamaguchi has disclosed no relevant financial relationships.

Content Reviewer

Esther Nyarko, PharmD

Associate Director, Accreditation and Compliance, Medscape LLC

Disclosures

Disclosure: Esther Nyarko, PharmD, has disclosed no relevant financial relationships.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements

For Physicians

The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.50 continuing professional development credits (CPD).

Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

From Medscape Education

CPD

TPO-RA in Adult Patients With ITP: Experts Discuss the Latest Developments

Authors: Drew Provan, MD, FRCP, FRCPath; Hanny Al-Samkari, MD; Maria L. Lozano, MD, PhDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED

CPD Released: 5/7/2021

Valid for credit through: 5/7/2022

processing....

CPD Information Download Slides

Activity Transcript

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient is intended or should be inferred.

The material presented here does not necessarily reflect the views of WebMD Global, LLC or companies that support educational programming on medscape.org. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

References

Faculty and Disclosures

Moderator

Drew Provan, MD, FRCP, FRCPath

Panelists

Hanny Al-Samkari, MD

Maria L. Lozano, MD, PhD

Editors

Sanneke Koekkoek

Yoji Yamaguchi

Content Reviewer

Esther Nyarko, PharmD

Peer Reviewer

CPD

TPO-RA in Adult Patients With ITP: Experts Discuss the Latest Developments

Target Audience and Goal Statement

Disclosures

Moderator

Drew Provan, MD, FRCP, FRCPath

Panelists

Hanny Al-Samkari, MD

Maria L. Lozano, MD, PhD

Editors

Sanneke Koekkoek

Yoji Yamaguchi

Content Reviewer

Esther Nyarko, PharmD

Peer Reviewer

Accreditation Statements

For Physicians

Instructions for Participation and Credit

TPO-RA in Adult Patients With ITP: Experts Discuss the Latest Developments